vs
PEOPLES BANCORP INC（PEBO）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
PEOPLES BANCORP INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.7倍（$118.7M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 24.4%，领先359.6%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 3.7%）
该公司是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，同时也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构。它主营银行、投资、抵押贷款等相关金融业务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
PEBO vs RIGL — 直观对比
营收规模更大
PEBO
是对方的1.7倍
$69.8M
净利率更高
RIGL
高出359.6%
24.4%
两年增速更快
RIGL
近两年复合增速
3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.7M | $69.8M |
| 净利润 | $29.0M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 24.4% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | -8.7% | 1769.2% |
| 每股收益（稀释后） | $0.81 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PEBORIGL
| Q1 26 | $118.7M | — | ||
| Q4 25 | $117.3M | $69.8M | ||
| Q3 25 | $115.2M | $69.5M | ||
| Q2 25 | $114.5M | $101.7M | ||
| Q1 25 | $112.4M | $53.3M | ||
| Q4 24 | $111.6M | $57.6M | ||
| Q3 24 | $113.7M | $55.3M | ||
| Q2 24 | $110.3M | $36.8M |
净利润PEBORIGL
| Q1 26 | $29.0M | — | ||
| Q4 25 | $31.8M | $268.1M | ||
| Q3 25 | $29.5M | $27.9M | ||
| Q2 25 | $21.2M | $59.6M | ||
| Q1 25 | $24.3M | $11.4M | ||
| Q4 24 | $26.9M | $14.3M | ||
| Q3 24 | $31.7M | $12.4M | ||
| Q2 24 | $29.0M | $-1.0M |
毛利率PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | 32.4% | 33.2% | ||
| Q3 25 | 33.0% | 40.9% | ||
| Q2 25 | 24.0% | 60.1% | ||
| Q1 25 | 27.9% | 23.9% | ||
| Q4 24 | 31.2% | 28.9% | ||
| Q3 24 | 36.0% | 25.4% | ||
| Q2 24 | 32.5% | 1.2% |
净利率PEBORIGL
| Q1 26 | 24.4% | — | ||
| Q4 25 | 27.1% | 384.0% | ||
| Q3 25 | 25.6% | 40.2% | ||
| Q2 25 | 18.5% | 58.6% | ||
| Q1 25 | 21.7% | 21.5% | ||
| Q4 24 | 24.1% | 24.9% | ||
| Q3 24 | 27.9% | 22.5% | ||
| Q2 24 | 26.3% | -2.8% |
每股收益（稀释后）PEBORIGL
| Q1 26 | $0.81 | — | ||
| Q4 25 | $0.89 | $14.11 | ||
| Q3 25 | $0.83 | $1.46 | ||
| Q2 25 | $0.59 | $3.28 | ||
| Q1 25 | $0.68 | $0.63 | ||
| Q4 24 | $0.76 | $0.82 | ||
| Q3 24 | $0.89 | $0.70 | ||
| Q2 24 | $0.82 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.9M | $155.0M |
| 总债务越低越好 | $691.3M | $52.5M |
| 股东权益账面价值 | $1.2B | $391.5M |
| 总资产 | $9.6B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.57× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PEBORIGL
| Q1 26 | $82.9M | — | ||
| Q4 25 | $189.0M | $155.0M | ||
| Q3 25 | $190.2M | $137.1M | ||
| Q2 25 | $186.1M | $108.4M | ||
| Q1 25 | $187.0M | $77.1M | ||
| Q4 24 | $217.7M | $77.3M | ||
| Q3 24 | $283.7M | $61.1M | ||
| Q2 24 | $235.9M | $49.1M |
总债务PEBORIGL
| Q1 26 | $691.3M | — | ||
| Q4 25 | $204.1M | $52.5M | ||
| Q3 25 | $227.3M | $60.0M | ||
| Q2 25 | $232.4M | $60.0M | ||
| Q1 25 | $237.0M | $60.0M | ||
| Q4 24 | $238.1M | $60.0M | ||
| Q3 24 | $236.8M | $60.0M | ||
| Q2 24 | $234.3M | $60.0M |
股东权益PEBORIGL
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $391.5M | ||
| Q3 25 | $1.2B | $117.6M | ||
| Q2 25 | $1.2B | $81.9M | ||
| Q1 25 | $1.1B | $18.6M | ||
| Q4 24 | $1.1B | $3.3M | ||
| Q3 24 | $1.1B | $-14.6M | ||
| Q2 24 | $1.1B | $-29.9M |
总资产PEBORIGL
| Q1 26 | $9.6B | — | ||
| Q4 25 | $9.6B | $513.6M | ||
| Q3 25 | $9.6B | $242.5M | ||
| Q2 25 | $9.5B | $206.7M | ||
| Q1 25 | $9.2B | $176.0M | ||
| Q4 24 | $9.3B | $164.0M | ||
| Q3 24 | $9.1B | $139.4M | ||
| Q2 24 | $9.2B | $128.4M |
负债/权益比PEBORIGL
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.17× | 0.13× | ||
| Q3 25 | 0.19× | 0.51× | ||
| Q2 25 | 0.20× | 0.73× | ||
| Q1 25 | 0.21× | 3.23× | ||
| Q4 24 | 0.21× | 18.25× | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | $134.7M | $22.0M | ||
| Q3 25 | $14.4M | $24.0M | ||
| Q2 25 | $50.7M | $30.5M | ||
| Q1 25 | $34.3M | $-893.0K | ||
| Q4 24 | $143.2M | $14.5M | ||
| Q3 24 | $34.1M | $21.7M | ||
| Q2 24 | $32.1M | $302.0K |
自由现金流PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | $128.7M | — | ||
| Q3 25 | $12.7M | — | ||
| Q2 25 | $49.2M | — | ||
| Q1 25 | $31.5M | — | ||
| Q4 24 | $136.4M | — | ||
| Q3 24 | $33.2M | — | ||
| Q2 24 | $30.2M | — |
自由现金流率PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | 109.7% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 43.0% | — | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q3 24 | 29.2% | — | ||
| Q2 24 | 27.4% | — |
资本支出强度PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 1.7% | — |
现金转化率PEBORIGL
| Q1 26 | — | — | ||
| Q4 25 | 4.24× | 0.08× | ||
| Q3 25 | 0.49× | 0.86× | ||
| Q2 25 | 2.39× | 0.51× | ||
| Q1 25 | 1.41× | -0.08× | ||
| Q4 24 | 5.32× | 1.01× | ||
| Q3 24 | 1.08× | 1.75× | ||
| Q2 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PEBO
| Net Interest Income | $90.4M | 76% |
| Noninterest Income | $28.3M | 24% |
RIGL
暂无分部数据
